Pregnancy and Metabolic-Associated Fatty Liver Disease

• Claudia Mandato ^[1] ; Nadia Panera ^[2] ; Anna Alisi ^[2]
  1. [1] University of Salerno

     University of Salerno

     Fisciano, Italia

     
  2. [2] Genetics of Complex Phenotypes Research Unit, Bambino Gesù Children’s Hospital, IRCCS, Viale S. Paolo, 15, Rome 00146, Italy
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 3, 2023, págs. 521-531
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Metabolic-associated fatty liver disease (MAFLD), the term proposed to substitute nonalcoholic fatty liver disease, comprises not only liver features but also potentially associated metabolic dysfunctions. Since experimental studies in mice and retrospective clinical studies in humans investigated the association between nonalcoholic fatty liver disease during pregnancy and the adverse clinical outcomes in mothers and offspring, it is plausible that MAFLD may cause similar or worse effects on mother and the offspring. Only a few studies have investigated the possible association of maternal MAFLD with more severe pregnancy-related complications. This article provides an overview of the evidence for this dangerous liaison.